小细胞肺癌患者NLR和PLR的预后价值分析  

Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Patients with Small Cell Lung Cancer

作　　者：宋志远 代婉婷 杨自为 汪峣 张家玉[1] Song Zhiyuan;Dai Wanting;Yang Ziwei;Wang Yao;Zhang Jiayu(Department of Oncology,Yichang Central People’s Hospital,The First College of Clinical Medical Science,China Three Gorges University&Cancer Center,China Three Gorges University,Yichang 443003,China)

机构地区：[1]三峡大学第一临床医学院[宜昌市中心人民医院]肿瘤科&三峡大学肿瘤防治中心,湖北宜昌443003

出　　处：《巴楚医学》2022年第2期21-25,共5页Bachu Medical Journal

基　　金：国家自然科学基金面上项目(No:81270418)。

摘　　要：目的:探讨初诊小细胞肺癌(SCLC)患者外周血中性粒细胞/淋巴细胞比值(NLR)和血小板/淋巴细胞比值(PLR)的预后价值。方法:选取我院2017年1月1日~2018年12月31日初诊SCLC患者为研究对象,收集其临床资料及相关血液学指标的实验数据,回顾性分析其与生存的相关性。根据ROC曲线确定NLR、PLR界值,生存分析采用Kaplan-Meier法,Cox模型进行SCLC预后的多因素分析。结果:NLR=2.28,PLR=161作为评价的分界点,低NLR组较高NLR组生存期显著延长(18.00月vs. 6.34月,P<0.001)、低PLR组较高PLR组生存期显著延长(15.05月vs. 4.10月,P<0.001)。NLR(P<0.001,HR=3.381,95%CI:2.035~5.619)、PLR(P<0.001,HR=3.311,95%CI:2.089~5.248)、初始分期(P=0.004,HR=1.879,95%CI:1.218~2.898)及是否完成2周期EP方案化疗(P<0.001,HR=0.262,95%CI:0.174~0.395)是影响SCLC患者生存的独立影响因素。结论:NLR和PLR都是SCLC患者预后的独立影响因素,也是预测其总生存的有效指标。Objective: To investigate the prognostic value of peripheral blood neutrophil-to-lymphocyte(NLR) and platelet-to-lymphocyte ratio(PLR) in patients with newly diagnosed small cell lung cancer(SCLC). Methods: Newly diagnosed SCLC patients in our hospital from January 1, 2017 to December 31, 2018 were selected as subjects. The clinical data and experimental data of related hematological indexes were collected, and the correlation with survival was analyzed retrospectively. The cutoff values of NLR and PLR were determined according to the receiver operating characteristic curve(ROC). Kaplan-Meier method was used for survival analysis, and Cox model was performend for multivariate analysis of SCLC prognosis. Results: The cutoff value of NLR and PLR was 2.28 and 161, respectively. The survival time of the low NLR group and the low PLR group were significantly longer than that of the high NLR group and the high PLR group(18.00 months vs. 6.34 months, P<0.001;15.05 months vs. 4.10 months, P<0.001). Multivariate analysis showed that NLR(P <0.001, HR=3.381, 95%CI: 2.035~5.619), PLR(P <0.001, HR=3.311, 95%CI: 2.089~5.248), initial staging(P =0.004, HR=1.879, 95%CI: 1.218~2.898) and whether or not to complete at least 2 cycles of EP regimen chemotherapy(P<0.001, HR=0.262,95%CI: 0.174~0.395) were independent factors affecting the survival of patients with SCLC. Conclusion: NLR and PLR are independent prognostic factors and effective indicators for predicting overall survival in patients with SCLC.

关 键 词：小细胞肺癌 中性粒细胞/淋巴细胞比值 血小板/淋巴细胞比值 

分 类 号：R734.2[医药卫生—肿瘤]